Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients
Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients
About this item
Full title
Author / Creator
Publisher
London: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Background Nivolumab is an anti-PD1 antibody that has dramatically improved metastatic melanoma patients' outcomes. Nevertheless, many patients are resistant to PD-1 inhibition, occasionally experiencing severe off-target immune toxicity. In addition, no robust and reproducible biomarkers have yet been validated to identify the correct selection of...
Alternative Titles
Full title
Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_fc778616ad9c4244b22051d8743c7e29
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_fc778616ad9c4244b22051d8743c7e29
Other Identifiers
ISSN
1479-5876
E-ISSN
1479-5876
DOI
10.1186/s12967-023-04184-6
